Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q2 2025 value amounting to $78000.0.

  • Arcutis Biotherapeutics' Capital Expenditures changed N/A to $78000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $686000.0, marking a year-over-year increase of 36040.27%. This contributed to the annual value of $143000.0 for FY2024, which is 6658.88% down from last year.
  • According to the latest figures from Q2 2025, Arcutis Biotherapeutics' Capital Expenditures is $78000.0.
  • Arcutis Biotherapeutics' Capital Expenditures' 5-year high stood at $608000.0 during Q1 2025, with a 5-year trough of $6000.0 in Q3 2022.
  • Over the past 5 years, Arcutis Biotherapeutics' median Capital Expenditures value was $123000.0 (recorded in 2022), while the average stood at $172333.3.
  • In the last 5 years, Arcutis Biotherapeutics' Capital Expenditures skyrocketed by 125121.95% in 2021 and then plummeted by 9562.04% in 2022.
  • Over the past 5 years, Arcutis Biotherapeutics' Capital Expenditures (Quarter) stood at $261000.0 in 2021, then tumbled by 52.87% to $123000.0 in 2022, then crashed by 95.12% to $6000.0 in 2023, then surged by 2283.33% to $143000.0 in 2024, then crashed by 45.45% to $78000.0 in 2025.
  • Its Capital Expenditures stands at $78000.0 for Q2 2025, versus $608000.0 for Q1 2025 and $143000.0 for Q3 2024.